cJun targeted SPEARs inhibit the interaction of cJun with cFos and disrupt AP-1 complex formation, thereby inhibiting oncogenic activity.
Activator protein 1 (AP-1) is a transcription complex comprised of Jun and Fos protein subunits with involvement in a wide range of cellular processes including proliferation, apoptosis and differentiation. Dysregulation of the AP-1 complex drives the expression of oncogenic factors such as cyclin D, E2F and DP1, and has been observed in breast, ovarian, liver, skin, bone, lung, endometrial, and colorectal tumors, as well as many hematologic malignancies.
cJun program is currently in lead optimization
In preclinical studies to date, our cJun SPEAR candidates have demonstrated binding to cJun, disruption of the cJun/cFos AP-1 complex, and in vitro biologic activity.